These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3653232)

  • 1. Bioavailability of disopyramide in normal volunteers using unbound concentration.
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1987; 32(6):625-9. PubMed ID: 3653232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate- versus controlled-release disopyramide: importance of saturable binding.
    Davies RF; Siddoway LA; Shaw L; Barbey JT; Roden DM; Woosley RL
    Clin Pharmacol Ther; 1993 Jul; 54(1):16-22. PubMed ID: 8330460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative bioavailability of two disopyramide capsules in humans based on total, unbound, and unbound enantiomer concentrations.
    Takahashi H; Ogata H; Shimizu M; Hashimoto K; Masuhara K; Kashiwada K; Someya K
    Biopharm Drug Dispos; 1993 Jul; 14(5):409-18. PubMed ID: 8218959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination kinetics and urinary excretion of disopyramide in human healthy volunteers.
    Bonde J; Jensen NM; Pedersen LE; Graudal NA; Angelo HR; Kampmann JP
    Pharmacol Toxicol; 1988 May; 62(5):298-301. PubMed ID: 3413032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of neglecting nonlinear plasma-protein binding on disopyramide bioavailability studies.
    Upton RA; Williams RL
    J Pharmacokinet Biopharm; 1986 Aug; 14(4):365-79. PubMed ID: 3772738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms.
    Piscitelli DA; Fischer JH; Schoen MD; Hoon TJ; Bauman JL
    J Clin Pharmacol; 1994 Aug; 34(8):823-8. PubMed ID: 7962670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
    Hasselström J; Enquist M; Hermansson J; Dahlqvist R
    Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
    Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
    Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations.
    Sagawa K; Mohri K; Shimada S; Shimizu M; Muramatsu J
    Eur J Clin Pharmacol; 1997; 52(1):65-9. PubMed ID: 9143870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of concentration-dependent binding to plasma proteins on the pharmacokinetics and pharmacodynamics of disopyramide.
    Giacomini KM; Blaschke TF
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():42-8. PubMed ID: 6705426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition kinetics of disopyramide in human healthy volunteers described by an open three compartment model.
    Bonde J; Jensen NM; Pedersen LE; Angelo HR; Rasmussen SN; Trap-Jensen J; Kampmann JP
    Pharmacol Toxicol; 1989 May; 64(5):412-6. PubMed ID: 2771866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.
    Cunningham JL; Shen DD; Shudo I; Azarnoff DL
    Clin Pharmacokinet; 1977; 2(5):373-83. PubMed ID: 21054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.